Sheri Wilcox has spent more than two decades at the forefront of the proteomics revolution to transform biomedicine. At Nautilus, she leads the development of short-epitope binding reagents that enable its platform to uncover novel scientific insights about the proteome. Sheri’s track record also includes positions at SomaLogic, where she was instrumental in the building of its proteomics platform and in bolstering its library of aptamers to 7,000 targets, and Pharmacia prior to its merger with Pfizer. Sheri holds a Ph.D. from The Scripps Research Institute, and a B.S. from Vanderbilt University.